Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230283 | 1.00 | TACR1 (0.62) | TACR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6607533 | 0.99 | TACR1 (0.61) | TACR1CYP2D6 | |
| SCHEMBL6074291 | 0.97 | TACR1 (0.62) | TACR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6074552 | 0.96 | TACR1 (0.61) | TACR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6074558 | 0.96 | TACR1 (0.61) | TACR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL7597131 | 0.92 | TACR1 (0.61) | TACR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6605543 | 0.92 | TACR1 (0.61) | TACR1CYP2D6 | |
| SCHEMBL6073522 | 0.91 | TACR1 (0.61) | TACR1CYP2D6 | |
| SCHEMBL6073720 | 0.91 | TACR1 (0.61) | TACR1CYP2D6 | |
| SCHEMBL7118326 | 0.91 | TACR1 (0.61) | TACR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220274-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-20040001895-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-01 | — | — | US | disclosed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1099446-A2 | Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1095655-A2 | NK-1 receptor antagonists and eletriptan for the treatment of migraine | Pfizer Products Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TACR1 1/4885CYP2D6 1499/4885 |
| US-20040001895-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885CYP2D6 1323/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | TACR1 5/4885CYP2D6 1204/4885 |
| US-20040220274-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885CYP2D6 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.